ChemicalBook >> CAS DataBase List >>ARRY-614

ARRY-614

CAS No.
945614-12-0
Chemical Name:
ARRY-614
Synonyms
ARRY-614;pexmetinib,ARRY-614;Autophagy,p38 MAPK,ARRY 614,Pexmetinib,Inhibitor,ARRY614,inhibit;N-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)-N'-[5-fluoro-2-[1-(2-hydroxyethyl)-1H-indazol-5-yloxy]benzyl]urea;1-(3-(tertbutyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)benzyl)urea;1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea;Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[[5-fluoro-2-[[1-(2-hydroxyethyl)-1H-indazol-5-yl]oxy]phenyl]methyl]-
CBNumber:
CB22725624
Molecular Formula:
C31H33FN6O3
Molecular Weight:
556.63
MDL Number:
MFCD28502055
MOL File:
945614-12-0.mol
MSDS File:
SDS
Last updated:2023-06-08 09:03:09

ARRY-614 Properties

Boiling point 694.1±55.0 °C(Predicted)
Density 1.28±0.1 g/cm3(Predicted)
storage temp. Store at -20°C
solubility insoluble in H2O; ≥107.6 mg/mL in DMSO; ≥113 mg/mL in EtOH
form solid
pka 13.00±0.46(Predicted)
FDA UNII 3750D0U8B5

SAFETY

Risk and Safety Statements

ARRY-614 price More Price(14)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 26187 Pexmetinib 945614-12-0 1mg $37 2024-03-01 Buy
Cayman Chemical 26187 Pexmetinib 945614-12-0 10mg $283 2024-03-01 Buy
Cayman Chemical 26187 Pexmetinib 945614-12-0 5mg $151 2024-03-01 Buy
TRC P293620 Pexmetinib 945614-12-0 100mg $900 2021-12-16 Buy
TRC P293620 Pexmetinib 945614-12-0 5mg $135 2021-12-16 Buy
Product number Packaging Price Buy
26187 1mg $37 Buy
26187 10mg $283 Buy
26187 5mg $151 Buy
P293620 100mg $900 Buy
P293620 5mg $135 Buy

ARRY-614 Chemical Properties,Uses,Production

Uses

Pexmetinib is a potent and orally bioavailable dual p38 MAPK/Tie-2 inhibitor preventing tumor growth.

Biological Activity

pexmetinib (arry-614) is a potent inhibitor of cytokine synthesis, via the dual inhibition of p38 mitogen-activated protein kinase (mapk), and tie2/tek receptor tyrosine kinase. the in vitro ic50 values of arr y-614 for both tie2 and p38 mitogen-activated protein kinase are 1000 ng/ml and 100 ng/ml, respectively [1, 2].p38 is a group of mitogen-activated protein kinases. mapks are activated by the dual phosphorylation of tyr and thr residues in the thr-xaa-tyr motif in subdomain viii. data indicated that p38 mapk may mediate signaling to the nucleus [3].arry-614 is active against mapk and tie2/tek receptor tyrosine kinase in cells. in primary human bone marrow stromal cells, arry-614 inhibited basal cytokines with an ic50 value ranging from 50-100 nm [4].in dose escalation or expansion cohorts, treatment with arry-614 either once daily or twice daily was applied to forty-five patients. arry-614 reduced the levels of circulating biomarkers and the p38 mapk activation of bone marrow [1]. in ex vivo stimulated human whole blood, lps-induced cytokines was inhibited by arry-614 with an ic50 value ranging from 50-120 nm. arry-614 inhibited the release of il-6 from sea- or lps-challenged mice with an ed50 value less than 10 mg/kg. combining arry-614 with lenalidomide inhibited both pro-inflammatory cytokines and tumor growth in vivo with higher potency, compared with either agent alone [4].

References

[1]. garcia-manero g, khoury hj, jabbour e, et al. a phase i study of oral arry-614, a p38 mapk/tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. clinical cancer research, 2015, 21(5): 985-994.
[2]. wollenberg la, corson dt, nugent ca, et al. an exploratory, randomized, parallel-group, open-label, relative bioavailability study with an additional two-period crossover food-effect study exploring the pharmacokinetics of two novel formulations of pexmetinib (arry-614). clinical pharmacology: advances and applications, 2015, 7: 87.
[3]. raingeaud j, whitmarsh aj, barrett t, et al. mkk3-and mkk6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. molecular and cellular biology, 1996, 16(3): 1247-1255.
[4]. winski s, humphries m, yeh t, et al. activity of arry-614, an inhibitor of p38 map kinase and angiogenic targets, in hematologic malignancies. cancer research, 2009, 69(9 supplement): 331-331.

ARRY-614 Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 63)Suppliers
Supplier Tel Email Country ProdList Advantage
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32686 60
BOC Sciences
+1-631-485-4226 inquiry@bocsci.com United States 19553 58
career henan chemical co
+86-0371-86658258 15093356674; factory@coreychem.com China 29826 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471 sales@sarms4muscle.com China 10523 58
InvivoChem
+1-708-310-1919 +1-13798911105 sales@invivochem.cn United States 6393 58
Hangzhou MolCore BioPharmatech Co.,Ltd.
+86-057181025280; +8617767106207 sales@molcore.com China 49739 58
TargetMol Chemicals Inc.
+1-781-999-5354 support@targetmol.com United States 19973 58
Aladdin Scientific
+1-833-552-7181 sales@aladdinsci.com United States 57511 58
Wuhan Jingkang en Biomedical Technology Co., Ltd
+8613720134139 orders@jknbiochem.com China 4604 58
Amadis Chemical Company Limited
571-89925085 sales@amadischem.com China 131981 58

View Lastest Price from ARRY-614 manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
	Pexmetinib pictures 2019-12-23 Pexmetinib
945614-12-0
US $1.00 / KG 1g Min98% HPLC g/kg /ton Career Henan Chemical Co
  • 	Pexmetinib pictures
  • Pexmetinib
    945614-12-0
  • US $1.00 / KG
  • Min98% HPLC
  • Career Henan Chemical Co

ARRY-614 Spectrum

N-(3-tert-Butyl-1-p-tolyl-1H-pyrazol-5-yl)-N'-[5-fluoro-2-[1-(2-hydroxyethyl)-1H-indazol-5-yloxy]benzyl]urea 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[[5-fluoro-2-[1-(2-hydroxyethyl)indazol-5-yl]oxyphenyl]methyl]urea ARRY-614 pexmetinib,ARRY-614 1-(3-(tertbutyl)-1-(p-tolyl)-1H-pyrazol-5-yl)-3-(5-fluoro-2-((1-(2-hydroxyethyl)-1H-indazol-5-yl)oxy)benzyl)urea Urea, N-[3-(1,1-dimethylethyl)-1-(4-methylphenyl)-1H-pyrazol-5-yl]-N'-[[5-fluoro-2-[[1-(2-hydroxyethyl)-1H-indazol-5-yl]oxy]phenyl]methyl]- Autophagy,p38 MAPK,ARRY 614,Pexmetinib,Inhibitor,ARRY614,inhibit 945614-12-0 C31H33FN6O3